title: Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
abstract: A 65-year-old woman with a 48-year history of Behçet's disease associated with nephrotic syndrome is described. Immunofluorescence study revealed IgA nephropathy. Following treatment with an angiotensin II type-I receptor-blocker, an anti-platelet drug, and an HMG-CoA reductase inhibitor, accompanied by dietary restrictions of protein and sodium, proteinuria was markedly decreased. This report describes our experience with a rare entity of Behçet's disease complicated by nephrotic syndrome due to IgA nephropathy. Routine urine examination and renal biopsy are needed for the detection and diagnosis of renal problems with Behçet's disease.
authors.affiliation: Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine, Kanazawa-ku, Yokohama 236-0004, Japan. tatsuo_h@med.yokohama-cu.ac.jp
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Toya
authors.forename: Minoru
authors.initials: M
authors.lastname: Kihara
authors.forename: Machiko
authors.initials: M
authors.lastname: Yabana
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Inayama
authors.forename: Ken-Ichiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kousaku
authors.initials: K
authors.lastname: Iwatsubo
authors.forename: Mai
authors.initials: M
authors.lastname: Yanagi
authors.forename: Jin
authors.initials: J
authors.lastname: Oshikawa
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Kokuho
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kuji
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Yoshida
authors.forename: Kouichi
authors.initials: K
authors.lastname: Tamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Umemura
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000069059:Atorvastatin; D001528:Behcet Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D004109:Dilazep / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005922:Glomerulonephritis, IGA / Q000150:complications*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000209:etiology; D011758:Pyrroles / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D013777:Tetrazoles; D014665:Vasodilator Agents; D000069059:Atorvastatin; D004109:Dilazep; C077793:candesartan cilexetil